Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hepalink takes 10% stake in ProMetic; companies sign R&D collaboration

Executive Summary

ProMetic Life Sciences Inc. (blood purification processes and drug candidates for various diseases) and heparin manufacturer Shenzhen Hepalink Pharmaceutical Co. Ltd. have established a joint R&D collaboration involving ProMetic's protein technologies. In addition, Hepalink is taking a 10.02% stake in ProMetic for $Cdn10mm ($9.6mm).

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies